Interesting2 May 2019 18:27
Statement regarding Price Movement
TURKU - FINLAND, 2 May 2019 - Faron Pharmaceuticals Ltd ("Faron") (AIM: FARN), the clinical stage biopharmaceutical company, notes the recent movement in its share price and the Company confirms that it knows of no operational or corporate reason for the share price move.
As noted in the Company's announcements on 26 March 2019 and 11 April 2019, the Company continues to progress both its key products, Clevegen and Traumakine. In particular, as announced, the Company has seen encourgaing early observations in the MATINS trial of potential early clinical benefits in dosed patients and the Company is currently engaged in partnering discussions with several parties. Whilst there can be no guarantee, the Company hope for a positive outcome from these negotiations during 2019